Acurx Pharmaceuticals Files 8-K on Financials
Ticker: ACXP · Form: 8-K · Filed: Mar 18, 2025 · CIK: 1736243
Sentiment: neutral
Topics: financial-condition, financial-statements, 8-k
Related Tickers: ACRX
TL;DR
ACRX filed an 8-K on March 18, 2025, detailing financial results and condition.
AI Summary
Acurx Pharmaceuticals, Inc. filed an 8-K on March 18, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 259 Liberty Avenue, Staten Island, NY.
Why It Matters
This filing provides investors with an update on Acurx Pharmaceuticals' financial performance and condition, which is crucial for evaluating the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) that does not appear to contain any new material events or significant negative news.
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant
- March 18, 2025 (date) — Date of earliest event reported
- 259 Liberty Avenue, Staten Island, NY 10305 (location) — Address of principal executive offices
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Acurx Pharmaceuticals, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was this 8-K filed?
This 8-K was filed on March 18, 2025.
What is Acurx Pharmaceuticals, Inc.'s state of incorporation?
Acurx Pharmaceuticals, Inc. is incorporated in Delaware.
Where are Acurx Pharmaceuticals, Inc.'s principal executive offices located?
Acurx Pharmaceuticals, Inc.'s principal executive offices are located at 259 Liberty Avenue, Staten Island, NY 10305.
What is the company's telephone number?
The company's telephone number is (917) 533-1469.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 18, 2025 regarding Acurx Pharmaceuticals, Inc. (ACXP).